Experts urge caution over drug company campaigns to destigmatize obesity

AI Summary

Experts writing in The BMJ warn that pharmaceutical-company campaigns to destigmatize obesity could allow companies that profit from its treatment to influence public debate and national policy. They support reducing stigma but urge caution about commercial interests shaping the conversation.

We should be wary of campaigns by pharmaceutical companies to destigmatize obesity, say experts in The BMJ. Michael Viggars and colleagues argue that, while destigmatizing obesity is the right thing to do, there is a risk that companies profiting from obesity treatment come to influence public conversation and national policy.